VENTURA COUNTY
HEALTH CARE PLAN

Prior Authorization DRUG Guidelines

Armodafinil (Nuvigil)

Effective Date: 7/21/2020
Date Developed: 7/21/2020 by Dr. H. Taekman
Last Approval Date: 8/18/2020; 8/3/2021, 2/1/22, 1/31/23

Armodafinil is a wakefulness promoting agent for oral administration.

Pre-Authorization Criteria:

A documented diagnosis of one of the following:

- Narcolepsy, confirmed by sleep lab evaluation **OR**
- Obstructive sleep apnea/hypopnea syndrome (OSAHS), confirmed by polysomnography (a study on sleep cycles and behavior) **AND** one of the following:
  - Member is currently using an oral/dental appliance
  - Member has undergone an uvulopalatopharyngoplasty (UPPP)
  - Member is greater than or equal to 65 yrs of age
  - Member has already had an adequate therapeutic trial of twelve weeks of continuous positive airway pressure (CPAP)/ bilevel positive airway pressure (BiPAP) treatment and meets ALL of the following:
    - Member is compliant with and currently using CPAP/BiPAP treatment
    - Member is experiencing excessive sleepiness despite CPAP/BiPAP use

Shift-work disorder: To improve wakefulness in patients with excessive sleepiness associated with shift-work disorder.

Precautions: Serious and life-threatening rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported; not recommended in patients with a history of left ventricular hypertrophy or patients with mitral valve prolapse who have developed mitral valve prolapse syndrome with previous CNS stimulant use; dosage reduction is recommended with severe hepatic impairment; Use caution in patients with a history of psychosis, depression, or mania; use reduced doses in elderly patients; check for drug interactions; Armodafinil is present in breast milk

Note: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Adult

Narcolepsy: Oral: 150 to 250 mg once daily in the morning

Obstructive sleep apnea (OSA): Oral: 150 to 250 mg once daily in the morning; doses >150 mg have not been shown to have an increased benefit.

Shift-work disorder: Oral: 150 mg given once daily ~1 hour prior to work shift.

Revision History:
Date Developed: 7/21/2020 by Howard Taekman, MD
Date Approved by P&T Committee: August 18, 2020
Date Reviewed/ Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 8/3/21
Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/1/22
Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/31/23

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
8/18/20	NEW	Howard Taekman, MD	NEW
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated pre-authorization criteria with additional diagnoses.
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review